Drugs / Dipeptiven
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT02130674 | Jan 2005 → Feb 2011 | traumatic brain injury | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT00732849 | Jun → Sep 2002 | — | Jagiellonian University | Completed | No outcome recorded |
| Phase 4 | NCT00558155 | Jun 2001 → Dec 2005 | gastric cancer, malignant pancreatic neoplasm | Jagiellonian University | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT05140772 Comparator | Jun 2020 → Dec 2021 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 4 | NCT00647036 Comparator | Jul 2009 → Dec 2011 | — | Institute of Child Health | Completed | No outcome recorded |
| — | NCT05822518 Comparator | Jun 2022 → Nov 2023 | urinary bladder cancer | Menoufia University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dipeptiven | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00732849 ↗ |
| Known as | alanyl-glutamine dipeptide | “Patients suffering from severe traumatic brain injury and requiring multimodal neuromonitoring during pharmacological coma will receive alanyl-glutamine dipeptide (Dipeptiven)...” NCT02130674 ↗ |
| Modality | Peptide | “Patients suffering from severe traumatic brain injury and requiring multimodal neuromonitoring during pharmacological coma will receive alanyl-glutamine dipeptide (Dipeptiven)...” NCT02130674 ↗ |
| Route | Intravenous | “IV administration daily for 7 days” NCT05140772 ↗ |